TORONTO, Nov. 8, 2023
/PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB:
MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company")
a pharmaceutical company specialized in precision-based
cannabinoids, is pleased to announce it will release its third
quarter financial results for the three and nine month periods
ended September 30, 2023, before
markets open on Tuesday, November 14,
2023.
MediPharm's executive management team will also host a
conference call and audio webcast on Tuesday, November 14, 2023 at 8:30 a.m. eastern time to discuss the Company's
financial results.
Audio
Conference Call Dial in Details:
Toll-free number: +1 (888) 330-2454 / International number: +1
(240) 789-2714
Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes
before the start of the call.
Audio
Webcast:
An audio webcast will be available by visiting the following
link here.
For those who are unable to participate on the live conference
call or webcast, a replay will be available at
https://www.medipharmlabs.com/investors approximately one day after
completion of the call.
About
MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development
and manufacture of purified, pharmaceutical-quality cannabis
concentrates, active pharmaceutical ingredients (API) and advanced
derivative products utilizing a Good Manufacturing Practices
certified facility with ISO standard-built clean rooms. MediPharm
Labs has invested in an expert, research driven team,
state-of-the-art technology, downstream purification methodologies
and purpose built facilities with five primary extraction lines for
delivery of pure, trusted and precision-dosed cannabis products for
its customers. Through its wholesale and white label platforms,
MediPharm Labs formulates, develops (including through sensory
testing), processes, packages and distributes cannabis extracts and
advanced cannabinoid-based products to domestic and international
markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug
Establishment Licence from Health Canada, becoming the only company
in North America to hold a
domestic Good Manufacturing Licence for the extraction of natural
cannabinoids. The Company carries out its operations in compliance
with all applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking statements and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that involves discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions, future events or performance (often but not always
using phrases such as "expects", or "does not expect", "is
expected", "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts", "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. Forward-looking statements are necessarily based upon a
number of estimates and assumptions that, while considered
reasonable, are subject to known and unknown risks, uncertainties,
and other factors which may cause the actual results and future
events to differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm to obtain adequate
financing; the delay or failure to receive regulatory approvals;
and other factors discussed in MediPharm's filings, available on
the SEDAR+ website a www.sedarplus.ca. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on the forward-looking statements and information
contained in this news release. Except as required by law,
MediPharm assumes no obligation to update the forward-looking
statements of beliefs, opinions, projections, or other factors,
should they change.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-sets-date-to-report-third-quarter-2023-financial-results-301982359.html
SOURCE MediPharm Labs Corp.